Howard W. Robin
2017
In 2017, Howard W. Robin earned a total compensation of $18.1M as President and Chief Executive Officer at Nektar Therapeutics, a 280% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,599,190 |
|---|---|
| Option Awards | $8,544,658 |
| Salary | $940,700 |
| Stock Awards | $6,884,888 |
| Other | $127,975 |
| Total | $18,097,411 |
Robin received $8.5M in option awards, accounting for 47% of the total pay in 2017.
Robin also received $1.6M in non-equity incentive plan, $940.7K in salary, $6.9M in stock awards and $128K in other compensation.
Rankings
In 2017, Howard W. Robin's compensation ranked 190th out of 14,666 executives tracked by ExecPay. In other words, Robin earned more than 98.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 190 out of 14,666 | 99th |
Division Manufacturing | 50 out of 5,770 | 99th |
Major group Chemicals And Allied Products | 13 out of 2,074 | 99th |
Industry group Drugs | 10 out of 1,730 | 99th |
Industry Pharmaceutical Preparations | 9 out of 1,329 | 99th |
Source: SEC filing on April 30, 2018.
Robin's colleagues
We found four more compensation records of executives who worked with Howard W. Robin at Nektar Therapeutics in 2017.
2017
John Nicholson
Nektar Therapeutics
Chief Operating Officer
2017
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2017
Stephen Doberstein
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2017
Maninder Hora
Nektar Therapeutics